Market Overview

Andrew Left: Exact Sciences Cologuard Test Is Not Worth The Cost

Andrew Left: Exact Sciences Cologuard Test Is Not Worth The Cost
Related EXAS
46 Biggest Movers From Yesterday
40 Stocks Moving In Friday's Mid-Day Session
Waiting For The Next Overreaction With Exact Sciences (Seeking Alpha)
Related UNH
Morgan Stanley: Quest Diagnostics Has Balanced Risk-Reward
Benzinga's Top Upgrades, Downgrades For March 8, 2018
Unitedhealth Group Inc (UNH) Vice Chmn, UHG and CEO, Optum Larry C Renfro Sold $5. ... (GuruFocus)

According to Andrew Left, EXACT Sciences Corporation (NASDAQ: EXAS)'s Cologuard may be a good test, but it's not worth the full $500-$600 cost. 

Left was responding to a report that UnitedHealth Group Inc (NYSE: UNH) had added the company's Cologuard, an alternative to a colonoscopy, to its Coverage Determination Guideline, which could lay to rest questions about the product's efficacy. 

United Health did not respond to a request for comment regarding the guideline change. 

Left told Benzinga the key thing to note in the story of Exact Sciences is what United Health would pay to insure the test. 

The news was first reported on BenzingaPro


Left is short Exact Sciences, and has a $20 price target. The stock traded at $34.97 in after hours trading at time of publication. 

Posted-In: Andrew Left Citron ResearchBiotech News Short Sellers Exclusives General Best of Benzinga


Related Articles (EXAS + UNH)

View Comments and Join the Discussion!